Review article

Implication of nuclear EGFR in the development of resistance to anticancer therapies

Wei-Chien Huang\textsuperscript{a,b,c,d,1,*}, Yun-Ju Chen\textsuperscript{a,e,f,1}, Mien-Chie Hung\textsuperscript{a,b,g,**}

\textsuperscript{a} Center for Molecular Medicine, China Medical University Hospital, Taichung 404, Taiwan
\textsuperscript{b} Graduate Institute of Cancer Biology, China Medical University, Taichung 404, Taiwan
\textsuperscript{c} The PhD Program for Cancer Biology and Drug Discovery, China Medical University, Taichung 404, Taiwan
\textsuperscript{d} Department of Biotechnology, Asia University, Taichung 413, Taiwan
\textsuperscript{e} Department of Medical Research, E-DA Hospital, Kaohsiung 824, Taiwan
\textsuperscript{f} Department of Biological Science and Technology, I-Shou University, Kaohsiung 824, Taiwan
\textsuperscript{g} Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

\textbf{A B S T R A C T}

Epidermal growth factor receptor (EGFR) was identified as a major oncogenic factor in various types of cancer, and thereby has been considered as an attractive therapeutic target for cancer therapy. The well-characterized classic function of this plasma membrane-bound receptor is transduction of extracellular mitogenic signals to a variety of intracellular downstream signaling cascades associated with tumorigenesis. Aberrantly expressed EGFR also undergoes direct nuclear translocation to induce transcription of genes associated with cell proliferation, cell cycle regulation, and tumor progression. Emerging evidence suggests the existence of a new role of nuclear EGFR signaling in conferring acquired resistance in response to various anticancer therapies. In this review, we summarize the current understanding of how EGFR translocates into the nucleus in response to ionizing radiation, chemotherapy, and anti-EGFR target agents. The emerging impact of nuclear EGFR in modulating the cellular sensitivity of cancer cells to these anticancer treatments will also be discussed. A better understanding of the nuclear EGFR pathways in response to anticancer therapies will facilitate the development of novel strategies to overcome the acquired resistance.

\textbf{Keywords:}
anticancer therapies
drug resistance
nuclear EGFR

1. Introduction

Epidermal growth factor receptor (EGFR, ErbB1), a receptor tyrosine kinase, is frequently overexpressed and widely involved in the etiology and progression of many types of cancer [1]. Cancer patients whose tumors aberrantly express EGFR tend to have a more aggressive disease and a shorter survival rate, so EGFR not only has been viewed as a predictive...
marker for poor clinical outcome but also intensely pursued as a therapeutic target [2]. EGFR activation through dimerization and autophosphorylation with ERBB family stimulates multiple intracellular downstream signaling pathways by recruiting effector proteins. Two major pathways initiated by the receptor tyrosine kinase are the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3 K)–Akt pathways [3,4]. Other important growth regulators in cancer in response to EGFR activation are the signal transducer and activator of transcription proteins (STATs), SRC tyrosine kinase, and mammalian target of rapamycin [5–7]. These signaling cascades integrate and transmit the EGFR activation into distinct transcriptional programs associated with proliferation, tumorigenesis, metastasis, and survival [3]. In addition to its well-characterized downstream signaling pathways, EGFR and other ErbB family have been found to enter the nucleus of multiple types of cancer cells and possess oncogenic functions, including gene transcription [8–12], DNA repair [13–15], regulation of enzyme activity [16], and translation [17], linking to the aggressiveness of tumors. Interestingly, the nuclear translocation of EGFR was also repeatedly observed in response to the constitutive treatment with different types of anticancer drugs [18–21] and ionizing radiation [14,22,23], suggesting that nuclear EGFR may play a crucial role in the development of therapy resistance. However, the role of nuclear EGFR in the development of resistance to anticancer therapies is still not fully understood. This review will summarize and discuss the current understanding of the nuclear functions of EGFR and its impact on tumor sensitivity to radiation, chemotherapy, and anti-EGFR target therapy.

2. Biological properties and clinical implication of nuclear EGFR in cancer

Following the first discovery of nuclear localization of EGFR in liver cancer cells [24], nuclear expression of EGFR and ErbB2 has been continually discovered in a variety of cancer types [8,10,25–31]. The first identified nuclear function of EGFR is regulation of gene transcription [10]. Although the association with AT-rich sequence (ATRS) of its target gene promoters has been proposed to be required for nuclear EGFR-activated gene transcription [10,21], the lack of a DNA-binding domain [10] suggests that nuclear EGFR targets promoters through binding to various transcriptional factors with DNA-binding domains and functions as a transcription cofactor rather than a DNA-binding transcription factor. In response to EGFR stimulation, the interaction of nuclear EGFR with signal transducer and activator of transcription-3 (STAT3) has been demonstrated to be required for nuclear EGFR-mediated inducible nitric oxide synthase (iNOS) [8] and cyclooxygenase-2 (COX-2) [9] expression. In addition, nuclear EGFR cooperates with STAT5 and E2F1 to enhance aurora A [32] and B-Myb [27] gene expression, respectively. Interestingly, our recent findings further revealed that nuclear EGFR also interacts with RNA helicase A (RHA) independent of its ATPase/helicase activity to associate with the promoter region of its target genes such as cyclin D1 and iNOS [33], indicating that RHA is a DNA-binding partner for nuclear EGFR in regulating its target gene expression. However, overexpression of the RHA-interaction domain (residues 645–1186) of EGFR is not sufficient and full length of EGFR is required to increase the promoter activity [33], suggesting that other unidentified components may be involved in the EGFR–RHA complex.

Given the fact that nuclear EGFR retains its tyrosine kinase activity, regulation of protein stability and enzymatic activity of its nuclear target proteins via tyrosine phosphorylation has been explored as another important nuclear function of EGFR. Proliferating cell nuclear antigen (PCNA) was the first identified nuclear substrate of EGFR tyrosine kinase [13]. Nuclear EGFR stabilized chromatin-bound PCNA protein via phosphorylation at its Tyr211 and preventing its polyubiquitination and proteasomal degradation. The increased PCNA Tyr211 phosphorylation by nuclear EGFR promotes cell proliferation and DNA repair, and is closely correlated with poor survival of breast cancer patients. In addition to targeting PCNA, nuclear EGFR was also found to enhance DNA repair via regulating DNA-dependent protein kinase (DNA–PK), an enzyme involved in repairing double-strand breaks and V(D)J recombination [34]. A substantial amount of DNA–PK was found to be colocalized with EGFR in anti-EGFR mAb-treated cells in the confocal microscope analysis [34]. The physical interaction between nuclear EGFR and DNA–PK was also observed in cancer cells treated with radiation [14] or anti-EGFR monoclonal antibody [34]. Furthermore, the nuclear level of EGFR is associated with phosphorylation of DNA–PK at residue T2609, an indicator of DNA–PK activity during nonhomologous end-joining DNA repair [14,22], and inhibition of EGFR signaling was accompanied by a reduction in the level and activity of DNA–PK in the nuclear fraction [34,35]. Although there is no evidence revealing that DNA–PK is directly phosphorylated by nuclear EGFR, these findings support that nuclear EGFR modulates DNA repair in response to DNA damage through regulating the kinase activity of the DNA–PK complex [36].

Although not all functions of nuclear EGFR have been elucidated, several studies suggest that nuclear EGFR may serve as a prognostic marker for poor clinical outcome. In a population of 130 breast cancer patients, tumor tissues from 37.7% of this cohort were immunostained positively for nuclear EGFR, and a significant inverse correlation existed between the high nuclear EGFR expression and overall survival [28]. Hadzisejdic et al also reported nuclear EGFR as an independent prognostic factor for mortality in another cohort of breast cancer patients [37]. The correlation between poor survival rate and high level of nuclear EGFR in the cancer cells was also observed in several cohorts of cancer patients with oral squamous carcinomas [28], oropharyngeal carcinomas [29], ovarian cancer [30], and esophageal squamous carcinomas [38]. These observations suggest that nuclear EGFR may be considered as a prognostic indicator for poor clinical outcome and also revealed a crucial role of nuclear EGFR in mediating tumor progression.

3. Nuclear EGFR facilitates the development of resistance to a variety of anticancer therapies

In most studies, nuclear localization of EGFR was observed in EGF-treated cancer cells or in the human primary tumor
Tissues. EGF induces EGFR nuclear localization rapidly and transiently within 2 h of treatment [39]. Coat protein complex I-mediated retrograde trafficking from the Golgi to the endoplasmic reticulum (ER) has been shown to regulate EGF-induced EGFR nuclear transport [40]. In addition to these physiological situations, our and others’ recent studies uncovered that some anticancer therapies also drive EGFR import into the nucleus of various cancer cells, adding a role of nuclear EGFR in the development of drug resistance. Unlike the transient nuclear localization by EGF stimulation, EGFR is steadily present in the nucleus in response to these anticancer treatments [14,18–22,36].

Ionizing radiation (IR) was found to stimulate EGFR nuclear transport in human bronchial and squamous carcinoma cells [14,18,41]. Other DNA-damaging stimuli, such as cisplatin and H2O2 also initiated EGFR internalization and subsequent nuclear import [14,42]. In the nucleus, EGFR has been demonstrated to play important roles in unhooking cisplatin-induced interstrand crosslinks and in repairing IR-induced strand breaks, indicating the involvement of nuclear EGFR in conferring chemoresistance and radioresistance [36]. Supporting this notion, our data further showed that after reconstruction of a functional nuclear localization sequence in its nuclear localization signal (NLS)-deleted mutant, EGFR is able to restore the DNA repair activity and consequently reduced the sensitivity of cancer cells to cisplatin [19].

In addition to IR and cisplatin, two EGFR-targeted therapeutic agents, cetuximab [41] and gefitinib [21], were also found to elicit the accumulation of EGFR in the nucleus. Cetuximab (Erbitux) is an EGFR-blocking antibody that has been approved for the treatment of patients with head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer. Ectopic expression of the NLS-tagged EGFR can reduce the sensitivity of NCI-H226 non-small cell lung cancer (NSCLC) cells to cetuximab both in vitro and in mouse xenografts [20], supporting the association of nuclear EGFR with tumor resistance to cetuximab. Gefitinib (ZD1839, Iressa), a small molecular weight EGFR kinase inhibitor, has been used for advanced and metastatic NSCLC with expression of activating EGFR mutants, such as EGFR L858R mutant [43], and most of NSCLC cancer patients bearing wild-type (wt) EGFR frequently are insensitive to this drug [43]. Our recent study reported that, in a wt EGFR-expressing cancer cell line, nuclear translocation of EGFR was increased in response to chronic treatment with gefitinib, and mediated the gene expression of breast cancer resistant protein (BCRP) to cause the development of drug resistance through efflux of gefitinib [21]. However, the nuclear translocation of EGFR and its mediated BCRP expression were only observed in cancer cells expressing wt EGFR but not its activating mutant, suggesting a possible mechanism explaining why gefitinib is not beneficial to most wt EGFR-expressing NSCLC patients [21,44]. The reason why the mutant EGFR lacks nuclear translocation ability is not clear. One possibility could be that the recently identified tracking mechanism of cell surface EGFR to the nucleus is impaired [40,45]. Similar to this observation, cells bearing EGFR L858R, which do not show nuclear expression, also possess less ability to repair cisplatin- and IR-induced DNA damage [36]. These studies imply a nuclear-specific role of wt EGFR in conferring the resistance in response to EGFR target therapy, chemotherapy, and IR.

EGFR tyrosine kinase activation has been reported to be required for the nuclear translocation of EGFR in response to EGF stimulation [10]. In addition to the wt form, EGFR is also present as truncated mutant (EGFRVIII) with constitutive kinase activity [46], and is associated with the aggressive biology of glioma [47]. The constitutively activated EGFR variant, EGFRVIII, is present in the nuclei of glioblastoma cells [48] and glioblastoma [48,49] revealing the crucial role of tyrosine kinase activation in the EGFR nuclear import. In response to irradiation, however, EGFR has been found to enter the nucleoplasm in a ligand-independent process that involves free radicals [14,50,51]. Furthermore, the L858R and exon 19 deletion mutants of EGFR, which exhibit constitutive kinase activity, did not show nuclear import after irradiation or cisplatin treatment [36], suggesting that other mechanisms, in addition to its kinase activity, may regulate the nuclear import of EGFR in response to these anticancer therapies. We have recently discussed the detailed mechanism by which the full-length receptors embedded in the endosomal membrane travel all the way from the cell surface to the early endosomes and pass through the nuclear pore complexes [40,45,52]. The specific regulations of EGFR nuclear import in response to different anticancer treatments will be described below.

4. Nuclear trafficking of EGFR in response to anticancer therapies

4.1. Ionizing radiation-induced EGFR nuclear localization involves karyopherin alpha and protein kinase C epsilon

Karyopherin proteins, also named importin, are nuclear transport factors and mediate the majority of nucleocytoplasmic transport [53]. We have demonstrated that interaction with importin beta is involved in the translocation of EGFR [39,45,54] and ErbB2 [55] into the nucleus through the nuclear port complex. Mutation of its NLS disrupts the interaction of EGFR with importins, indicating that EGFR may interact with importins through its NLS motif [39,54]. Dittmann et al showed that ionizing radiation also enhanced nuclear EGFR to form a complex with karyopherin alpha and Ran protein, which are essential for formation of a nuclear localization sequence-dependent nuclear import complex [14]. Their work suggested that IR triggers EGFR import into the nucleus in a karyopherin alpha-linked manner. In parallel with the role of nuclear EGFR in repairing DNA damage, karyopherin has also been considered as a marker for global chemoresistance and been reported as an important factor of tumorigenesis and progression of breast cancer [56]. Interestingly, the interaction between EGFR and the alpha form of karyopherin was only observed in response to IR but not EGF stimulation [14], suggesting that interactions with karyopherin alpha and beta forms may be responsible for radiation- and EGF-induced EGFR nuclear translocation, respectively. It would also be of great interest to know what the different regulations for the EGFR interactions with various karyopherins are in response to these stimuli.
Phosphorylation of EGFR Thr654 by protein kinase C epsilon (PKCε) is another regulation for EGFR nuclear translocation following irradiation [23]. EGFR Thr654 phosphorylation has been reported earlier to block Cbl induced ubiquitination and lysosomal degradation of EGFR, leading to EGFR stabilization [57]. PKCε has been identified as the kinase responsible for this modification following irradiation [18]. Furthermore, deletion of Thr654 blocked nuclear transport of EGFR, whereas mutation to Glu increased this shuttling, demonstrating that phosphorylation of this residue is essential for nuclear EGFR shuttling following irradiation [23]. Because the Thr654 phosphorylation is located within the NLS motif of EGFR, it raises the possibility that this phosphorylation by PKCε may regulate EGFR interaction with karyopherins.

4.2. Phosphorylation by Src family kinases drives EGFR nuclear import to reduce the sensitivity to cetuximab

Cetuximab (C225, Erbitux), a humanized monoclonal antibody, recognizes the extracellular domain of both wt EGFR and EGFRvIII has been approved as the second-line treatment after failure to chemotherapy or as the first-line treatment with radiation therapy for advanced HNSCC. Cetuximab is also used in combination with irinotecan for treating metastatic colorectal cancer after failure to chemotherapy. Reduction of c-Cbl-mediated internalization and degradation of EGFR under the chronic exposure to cetuximab leads to steady-state expression of EGFR, and the increased EGFR confers cetuximab resistance through binding and activating HER2 or HER3 to maintain signaling to MAPK and Akt pathways [58]. In addition to activating other receptor tyrosine kinases, the increased EGFR expression also caused the accumulation of EGFR in the nucleus [20]. In contrast to the ligand-independent manner in the IR-treated cells, the nuclear translocation of EGFR in cetuximab-resistant cells seems to rely on overexpression of several ErbB family ligands, including EGF, amphiregulin, heparin-binding (HB) EGF and beta-cellulin [20]. Overexpression of these ligands enhances the nuclear translocation of EGFR through Src family kinases (SFKs), and treatment of cetuximab-resistant cells with SFK inhibitor dasatinib (BMS354825) can resensitize cells to cetuximab [20]. Because inhibition of SFK activity and EGFR Y845 phosphorylation by dasatinib resulted in loss of cetuximab-induced nuclear EGFR expression (Fig. 1) and increase in membrane

---

**Fig. 1** — The nuclear roles of EGFR in conferring the resistance to irradiation, cisplatin, and anti-EGFR agents. In response to chronic treatment with irradiation and cisplatin, the nuclear translocation of EGFR is enhanced by PKCε and SFK-dependent phosphorylation at Thr654 and Tyr845, respectively, and by interaction with importins. The nuclear EGFR can interact with and activate DNA–PK to promote DNA repair, and thereby confers radioresistance and chemoresistance. In gefitinib-resistant cells, the compensatory Akt activation by IGFR signaling also facilitates EGFR nuclear import through phosphorylation of its Ser229. EGFR in the nucleus functions as a transcriptional regulator to mediate BCRP expression, which recognizes gefitinib and doxorubicin as substrates to result in the efflux of these drugs.
expression of EGF, Src may regulate the nuclear import of EGFR through phosphorylation of its Y845 and thereby contribute to cetuximab resistance [41].

4.3. Akt enhances wt EGFR nuclear import via phosphorylating its Ser229 response to gefitinib resistance

Gefitinib (ZD1839, Iressa) is the first small molecular inhibitor of EGFR tyrosine kinase. Although EGFR is overexpressed in many cancer types, targeting EGFR tyrosine kinase activity by gefitinib showed more dramatic efficacy and clinical benefits for NSCLC patients, particularly those characterized as East Asian, nonsmoker, adenocarcinoma histological type, and female gender, but only modest effects on many other cancer types [43]. The encouraging responses in these selected NSCLC patients to gefitinib showed strong association with specific gain-of-function mutations within the EGFR–tyrosine kinase domain [43,59]. Several mechanisms, including activation of c-MET and insulin growth factor receptor (IGFR) to raise the compensatory effects, have been shown to play a role in determining the sensitivity of wt EGFR-expressing cancer cell to gefitinib [64,65]. Interestingly, these mechanisms commonly elevate Akt activity was also associated with nuclear translocation of wt EGFR to mediate gefitinib resistance [21].

As in cetuximab-resistant cells [20] and irradiation-resistant cells [14,66], nuclear accumulation of EGFR in response to gefitinib resistance is observed in wt EGFR-expressing cell lines but not in EGFR mutant-expressing cell lines. We identified EGFR Ser229 as a novel Akt substrate and Ser229 phosphorylation of EGFR was detected in both nuclear and cytoplasmic fraction of gefitinib-resistant cells. Overexpression of Akt can dramatically increase the nuclear level of EGFR, and the Akt-mediated EGFR nuclear accumulation was attenuated by substitution of Ser229 to Ala, demonstrating that this phosphorylation is required for EGFR nuclear translocation [21]. Because elevated or continuous activation of Akt survival signaling is commonly observed in cancer cells with the characteristic of chemoresistance [19], radioresistance [14], or cetuximab insensitivity [20,58], Akt-dependent phosphorylation might be an general regulation for the nuclear translocation of EGFR in response to various anticancer therapies (as illustrated in Fig. 1). Currently, we further reported that sequential Akt-dependent phosphorylation and polyubiquitination are required for IκB kinase (IKKα) nuclear transportation in response to hepatitis B virus X protein overexpression [67]. Because ubiquitination has been widely found to be involved in protein nucleocytoplasmic shuttling [68–71], it raises the possibility that polyubiquitination of EGFR also occurs following Akt-dependent phosphorylation and mediates EGFR nuclear import. These observations suggest that phosphorylation by Akt may function as a common signal to drive the nuclear trafficking of target proteins, including EGFR. Other regulations, such as polyubiquitination, involving interactions with nuclear importer or exporter might be required to decide the destination of these cargo proteins. However, to elucidate the detail mechanism further studies are needed.

5. Molecular actions of nuclear EGFR in the development of resistance to anticancer therapies

5.1. Nuclear EGFR regulates DNA repair involves DNA–PK activation

The exploration of physical interaction between EGFR and DNA–PK [34], which is a major enzyme of nonhomologous end-joining DNA–double-strand break repair, initiated the extended studies to understand the roles of nuclear EGFR in DNA repair and resistance to DNA-damaging radiotherapy and alkylators (Fig. 1). After treatment with cisplatin and irradiation, the interaction of EGFR with the catalytic subunit of DNA–PK (DNA–PKcs) and its regulatory heterodimeric complex Ku70/80 was observed in the nucleus in vivo and in vitro [34]. Because the EGFR NLS mutation interrupts the association of EGFR with DNA–PKcs and reduces the nuclear localization of DNA–PKcs, EGFR has been suggested to co-translocate with DNA–PKcs into the nucleus and regulate the formation and activation of the DNA–PK complex after cisplatin treatment and IR [36]. Indeed, nuclear EGFR is associated with phosphorylation of DNA–PK at residue T2609, an indicator of DNA–PK activity during nonhomologous end-joining DNA repair [14,22]. Nuclear EGFR, in association with DNA–PK or Ku70/80, retains its intrinsic kinase activity [34]. Blockage of EGFR activation by its antibody cetuximab resulted in the decrease of DNA–PK activity, the increase of residual DNA damage, and the subsequent enhancement of the radiosensitivity of human A549 lung carcinoma cell line [22], suggesting that the tyrosine kinase activity of nuclear EGFR is required for the activation of the DNA–PK complex. However, the evidence revealing DNA–PK as a direct substrate of nuclear EGFR is lacking. In addition, EGFR tyrosine kinase activity may be essential but not sufficient for EGFR-dependent DNA–PKcs activation as overexpression of EGFR LNSL mutant, which contains both a constitutive activating mutation at L858 and an NLS mutation, cannot activate DNA–PKcs activity [36], further bolstering the crucial role of nuclear existence of EGFR in contributing to radioresistance and chemoresistance.

Although EGFR nuclear localization has been demonstrated to be required for modulation of cisplatin and IR-induced repair of DNA damage, the interaction between EGFR and DNA–PKcs was induced by cisplatin or IR but not by EGF stimulation or EGFR nuclear translocation per se [36]. Other mechanisms specifically elicited by DNA damage may be involved in the regulation of nuclear EGFR binding with DNA–PKcs. Interestingly, treatment with celecoxib, a COX-2 specific inhibitor, has been shown to obviously increase the radiosensitivity of multiple cancer cell lines via attenuating the radiation-induced EGFR nuclear transport and DNA–PK activation [72]. However, the radiosensitization by celecoxib seems to be independent of COX-2 activity [72]. Because celecoxib and its analogs possess an off-target effect on disrupting Akt signaling [73], which has been demonstrated to regulate EGFR nuclear import [21], it is worthy to further pursue whether irradiation induces the interaction between nuclear EGFR and DNA–PK in an Akt-dependent manner.
5.2. Nuclear EGFR functions as a transcription regulator to increase expression of gefitinib efflux pump

Despite that the effects of nuclear EGFR on the sensitivity to gefitinib are not well understood, nuclear presence of EGFR seems to be a general event in different gefitinib-treated cells [21]. As illustrated in Fig. 1, we have reported that nuclear EGFR functions as a transcription regulator to mediate BCRP/ABCG2 [21] and thereby confers gefitinib resistance [44]. The expression of BCRP/ABCG2, a well-known transporter of ATP-binding cassette (ABC) family involved in chemoresistance to doxorubicin as well as many other chemotherapies [74,75], was found in 46% of advanced NSCLC patients [76]. Several studies have demonstrated that gefitinib is also a substrate of BCRP/ABCG2 [44–46] and can be pumped out of the cells, resulting in development of gefitinib resistance [44]. Aberrant expression of this transporter was not only correlated with the intrinsic insensitivity of wt EGFR-expressing patients to gefitinib [44] but also increased in the wt EGFR-expressing NSCLC patient with acquired gefitinib resistance [77–79], revealing BCRP as a valuable marker to predict the clinical outcome of gefitinib-treated patients without EGFR activating mutations and as a potential target to overcome the acquired resistance to gefitinib [44]. The BCRP promoter contains ATRSs and has been found to be targeted by nuclear EGFR in an Akt-dependent manner [21]. Mutation of EGFR NLS or importin, which mediates the nuclear EGFR translocation, can abolish EGFR-dependent BCRP expression [21]. Although the promoter region of multiple drug resistance 1 (MDR-1/ABCB1), another ABC transporter, also contains ATRSs putative EGFR binding sites, the increase in MDR1 expression was not detected in the gefitinib-resistant cells [21]. Nuclear EGFR has been suggested to form a heteromeric transcription complex with the signal transducer and activator of transcription (Stat) proteins to mediate c-Myc expression in pancreatic cancer cells [80]. The overlapped binding site on BCRP promoter for Stat5 and ATRSs might account for the specific regulation of BCRP but not MDR-1 expression by nuclear EGFR [21].

(1) Are there additional mechanisms underlying nuclear EGFR-mediated resistance? Although the regulations of DNA–PK activation and BCRP expression by nuclear EGFR have been demonstrated to mediate the resistance to DNA-damaging treatment and gefitinib, respectively, the detail mechanisms remain unclear. Novel nuclear proteins phosphorylated and functionally modulated by nuclear EGFR in response to anticancer treatments await to be discovered. In addition, several target genes or proteins of nuclear EGFR implicated in tumorigenesis have been identified. It is worthy to further pursue whether these known targets of nuclear EGFR also contribute to the formation of drug resistance.

(2) Are there common mechanistic regulations that drive EGFR nuclear transport in response to different anticancer therapies? As described above, Akt activation has been viewed as a common signaling pathway to mediate the acquired resistance to multiple drugs and also plays a role in regulating gefitinib-induced EGFR nuclear translocation. Therefore, regulation by Akt may be a common mechanism for the EGFR import into the nucleus. However, other regulations, such as phosphorylation by SFK and PKCε, may compensate for this process.

(3) Does nuclear EGFR function as a key regulator in cross-resistance among irradiation, chemotherapy, and EGFR target therapy? The nuclear EGFR-mediated BCRP expression in gefitinib-resistance cells has been found to cause the cross-resistance to doxorubicin. It would be of great interest to examine whether chemoresistant cells also exhibit nuclear EGFR and BCRP expression to reduce their sensitivity to gefitinib. In addition, the nuclear import of EGFR and the subsequent DNA–PK activation have been commonly observed in response to various treatments including irradiation and cisplatin. Further studies are needed to demonstrate whether the nuclear EGFR-mediated DNA–PK activation can result in the cross-resistance between these DNA-damaging therapies. Addressing this question will provide very important information to determine the use and priority of anticancer therapies.

(4) Is there any efficient strategy for targeting nuclear EGFR signaling and thereby overcoming drug resistance? Once the nuclear role of EGFR in developing the resistance to anticancer therapies is extensively understood, blockage of nuclear EGFR signaling may be a new strategy to fight treatment resistance [23]. Indeed, targeting nuclear EGFR-dependent tyrosine phosphorylation of PCNA by blocking peptides has been shown to inhibit prostate cancer growth [81]. This finding revealed a promising strategy to overcome the nuclear EGFR-dependent resistance.

(5) Do other plasma membrane receptors also function in the nucleus to confer the resistance to cancer therapies? In addition to EGFR, nuclear translocations of other plasma membrane-bound receptors, such as HER2 [17,55], ErbB4 [82–86], and fibroblast growth factor receptor (FGFR) [87], have also been observed in various cancer types and are associated with etiology and tumor progression of these cancers. It would be of interest to understand whether these receptors in the nucleus also play a crucial role.

6. Perspectives and future directions

The studies in nuclear functions of EGFR conducted in the past decade have disclosed several important pathological roles of the nuclear EGFR pathway in tumorigenesis. Since Dittmann and colleagues reported the involvement of nuclear EGFR in the activation of the DNA–PK complex to mediate the DNA repair in response to irradiation [14], a novel aspect of nuclear EGFR in the development of acquired resistance to anticancer therapies has emerged. This finding has hence evoked many other studies on the mode of action of nuclear EGFR in conferring resistance to chemotherapy and EGFR target therapy. These studies have had profound implications for the development of a novel strategy to overcome drug resistance by targeting nuclear EGFR signaling. Although researchers gain new insights into the therapeutic impact of nuclear EGFR on human cancers, many questions remain to be addressed:
in determining the cellular sensitivity to anticancer therapies.

Collectively, elucidation of these aspects of nuclear EGFR will help us evaluate the possibility of using nuclear EGFR as a biomarker to predict the sensitivity to various anticancer treatments and develop novel strategies to prevent or overcome the acquired resistance. If this is the case, nuclear EGFR may serve as a biomarker to help us stratify patients for personalized cancer therapy.

Acknowledgments

We are grateful to Dr Stephanie Sellers for editing the manuscript. This work was supported by grants from the National Science Council of Taiwan (NSC-100-2320-B-039-021, NSC-100-2320-B-039-022-, NSC-97-2320-B-039-033-MY3, and NSC-99-3112-B-039-002 to W.C.H., and NSC-2632-B-001-MY3 to M.C.H.), the National Health Research Institutes of Taiwan (NHRI-EX-98-9812BC to W.C.H), Cancer Center Research of Excellence (DOH-TD-C-111-005 to M.C.H.), and the University of Texas MD Anderson Cancer Center/China Medical University Hospital Sister Institution Fund. All authors declare no financial interests.

References


Guillomar JS, de Bouard S, Valable S, Marteau L, Leuraud P, Guillamo JS, de Bouard S, Valable S, Marteau L, Leuraud P, et al. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in


